A Study on Rifampicin Resistant Mycobacterium Tuberculosis in a Tertiary Care Hospital Setting in Mysuru, India
DOI:
https://doi.org/10.37506/vs5mb149Keywords:
Tuberculosis, MDRTB, RRTB, Gene Xpert, LJ Media.Abstract
ABSTRACT: Tuberculosis (TB) remains one of the commonest infectious diseases in India, where control is difficult due to the emergence of multi-drug-resistant TB (MDR-TB). The rifampicin resistance (RR) is an important surrogate marker of MDR-TB. With increasing use of Xpert MTB/RIF a point of care molecular test for simultaneous detection of TB and resistance to rifampicin, a growing number of rifampicin resistant cases are being detected and notified. Traditional DST, on the other hand, is time-consuming, and there are significant issues with test consistency and drug stability in various culture media. The late detection of medication resistance could be a crucial factor in MDR-TB transmission. As a result, quick diagnostic assays are essential for efficient drug-resistant tuberculosis control. Hence the current study was aimed in determining the rate of rifampicin resistance in sputum smear positive cases by drug susceptibility testing (DST) using Lowenstein Jensen media (Proportion method) and comparing these results with that of CBNAAT results.
References
Prakash AK, Datta B, Tripathy JP, Kumar N, Chatterjee P, Jaiswal A. The clinical utility of cycle of threshold value of GeneXpert MTB/RIF (CBNAAT) and its diagnostic accuracy in pulmonary and extra-pulmonary samples at a tertiary care center in India. Indian Journal of Tuberculosis. 2018 Oct 1;65(4):296-302.
Sujatha R, Deepak S, Nashra A, Pratima. Detection of rifampicin resistance by CBNAAT in sputum samples at a tertiary centre in Kanpur. Rama Univ J Med Sci 2019;5:1-7.
Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
Sharma SK, Mohan A. Multidrug-resistant tuberculosis: A menace that threatens to destabilize tuberculosis control. Chest 2006;130:261-72
Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, et al. Determinants of drug-resistant tuberculosis: Analysis of 11 countries. Int J Tuberc Lung Dis 2001;5:887-93
Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis in India. Indian J Med Res 2004;120:377-86.
WHO Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. Available from: https://www.who.int/tb/ publications/2008/drs_report4_26feb08.pdf. [Last accessed on June 10, 2021].
O’Riordan P, Schwab U, Logan S, Cooke G, Wilkinson RJ, Davidson RN, et al. Rapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: Case–control study. PLoS One 2008;3:e3173.
World Health Organization. WHO Treatment Guidelines for DrugResistant Tuberculosis, 2016 Update. WHO/HTM/TB/2016.04 [Internet]. Geneva: World Health Organization; 2016. Available from: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/ resources/en/. [Last accessed on 2021 Nov 20].
Blakemore R, Story E, Helb D, Kop J, Banada P, Owens MR, et al. Evaluation of the analytical performance of the Xpert MTB/RIF assay. J ClinMicrobiol 2010;48:2495-501.
Das PK, Ganguly SB, Mandal B, Khan A. Prevalence of rifampicinresistantpediatric tuberculosis by cartridge-based nucleic acid amplification test at the intermediate reference laboratory under revised National Tuberculosis Control Program, India: A multidimensional approach. Biomed Biotechnol Res J 2018;2:300-5.
Borgdorff MW, Nico J. D. Nagelkerke, Petra E.W. de Haas and Dick van Soolingen. Transmission of mycobacterium tuberculosis depending on the age and sex of source cases. American Journal of Epidemiology. 2001;154(10):934–43.
Poornima MP, Shruthi MN, Chingale AL, Veena V, Nagaraja SB, Madhukeshwar AK. Cost of tuberculosis care in programmatic settings from Karnataka, India: Is it catastrophic for the patients? Tuberculosis Research and Treatment. 2020; 2020:1–9.
Wang J, Shen H. Review of cigarette smoking and tuberculosis in China: intervention is needed for smoking cessation among tuberculosis patients. BMC public health. 2009 Dec;9(1):1-9.
Bhattacharya P, Talukdar K, Barman B, Jamil M, Phukan P, Mobing H, et al. Clinical spectrum and medical comorbidities in tuberculosis: A hospital-based study in Northeast India. Cureus. 2020.
Sotgiu G, Centis R, D'ambrosio L, Migliori G. Tuberculosis Treatment and Drug Regimens. 2022.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
https://creativecommons.org/licenses/by-nc/2.0/deed.en